Evidence map›Paper›PMID 41561570›Full record

ArticleClinical parkinsonism & related disorders2026

Validation of the Norwegian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Guido Alves, Yvonne Stavland Sørenes, Veslemøy Hamre Frantzen, Michaela Dreetz Gjerstad, Anders Ledaal Bjørnestad, Jodi Maple-Grødem, Elin Bjelland Forsaa, Ylva Hivand Hiorth, Karen Herlofson, Espen Benjaminsen and 15 more

Abstract read
In one paragraph

Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Guido AlvesCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Yvonne Stavland SørenesCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Veslemøy Hamre FrantzenCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Michaela Dreetz GjerstadCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Anders Ledaal BjørnestadCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Jodi Maple-GrødemCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Elin Bjelland ForsaaCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Ylva Hivand HiorthCentre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Karen HerlofsonDepartment of Research, Sørlandet Hospital, Arendal, Norway.
Espen BenjaminsenDepartment of Neurology, Nordland Hospital Trust, Bodø, Norway.
Kari Anne BjørnaråDepartment of Neurology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Espen DietrichsDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Roberta BalestrinoVita-Salute San Raffaele University, Milan, Italy.
Carmen Gasca-SalasHM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
Chi-Ying R LinDepartment of Neurology, Baylor College of Medicine, Houston, TX, USA.
Alvaro Sanchez-FerroMovement Disorders Unit, Neurology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Michelle H S TosinDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Tiago A MestreParkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Monica M KurtisMovement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain.
Pablo Martinez-MartinCentro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute of Health Carlos III, Madrid, Spain.
Sheng LuoDepartment of Biostatistics & Bioinformatics, Duke University, Durham, NC, USA.
Luowen YuDepartment of Biostatistics & Bioinformatics, Duke University, Durham, NC, USA.
Glenn T StebbinsDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Christopher G GoetzDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
MDS COA Translation Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Movement Disorder Society-revised version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard assessment for evaluating Parkinson's disease (PD) symptoms and severity, but a validated Norwegian version is not yet available. We translated the original English MDS-UPDRS into Norwegian and tested the clinimetrics of the translated version following the MDS-established protocol for non-English language translations. Methods: Two independent teams translated the English version of the MDS-UPDRS into Norwegian. After review of the back-translated English version, cognitive pretesting was performed in twelve PD patients at one study site. This was followed by large-scale testing completed by 351 native Norwegian-speaking PD patients at six centers across Norway. We applied confirmatory and exploratory factor analyses to determine the validity of the Norwegian version. Additional analyses were performed to test the reliability of the translated scale. Results: Confirmatory factor analysis demonstrated that the factor structure of the Norwegian version was consistent with that of the English version, as indicated by comparative fit indexes of ≥0.90 for all four MDS-UPDRS parts. Exploratory factor analysis showed the same number of factors in each MDS-UPDRS part, compared to the English version, with some differences in item loadings. Cronbach's α values were >0.70 for all four MDS-UPDRS parts. Conclusion: The Norwegian language MDS-UPDRS has good construct validity and internal consistency, meeting the requirements to be designated as the Official Norwegian Version of the MDS-UPDRS. We recommend using this validated version in both research and clinical practice.

Indexed as

MDS-UPDRSParkinson’s diseaseReliabilityValidationValidity

Identifiers

PMID41561570
PMCPMC12814832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.